[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palmoplantar-pustulosis-ppp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palmoplantar-pustulosis-ppp":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,70,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100633721","phase-3-tofacitinib-plus-imatinib-in-moderate-to-severe-palmoplantar-pustulosis-100633721",false,"NCT07530367","Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis","A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib (Investigational Therapy) in Patients With Moderate-to-Severe Palmoplantar Pustulosis","inclusion Criteria:\n\nAge ≥ 18 years at the time of screening.\n\nDiagnosis of palmoplantar pustulosis (PPP) for at least 12 weeks prior to the screening visit.\n\nMay have a history of or concurrent plaque psoriasis.\n\nPPPASI score ≥ 12 at both the screening and baseline visits.\n\nPPP-IGA score ≥ 3 at both the screening and baseline visits.\n\nPresence of pustules on the palms and\u002For soles at both the screening and baseline visits, defined as pustule severity ≥ 2 in at least one region (one palm or one sole) based on the PPPASI.\n\nMust have a confirmed diagnosis of PPP by photographic adjudication.\n\nMale and\u002For female participants.\n\nFemale participants must not be pregnant, not be lactating (including feeding an infant by breast pump).\n\nExclusion Criteria:\n\nSignificant improvement in PPP symptoms between the screening and baseline visits, defined as a reduction in PPPASI score of ≥ 5 units.\n\nPresence of any of the following conditions: guttate psoriasis, erythrodermic psoriasis, generalized pustular psoriasis, acrodermatitis continua of Hallopeau, atopic dermatitis, dyshidrotic eczema, chronic hand eczema, or folliculitis.\n\nDrug-induced psoriasis (e.g., first onset or current flare triggered by beta-blockers, calcium channel inhibitors, lithium preparations, or TNF inhibitors) or drug-induced pustular psoriasis (e.g., acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis).\n\nActive infection or history of infection, as follows:\n\nAny active infection within 14 days prior to the baseline visit.\n\nSevere infection requiring hospitalization or intravenous anti-infective treatment within 8 weeks prior to the baseline visit.\n\nHistory of opportunistic infections, recurrent infections, or chronic infections that, in the investigator's opinion, would make participation in this study harmful to the participant.\n\nPositive test results for acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). Exclusion is defined as:\n\nHBV positive: 1) hepatitis B surface antigen positive, or 2) anti-hepatitis B core antibody positive.\n\nHCV positive: 1) hepatitis C antibody positive, and 2) confirmed by a confirmatory HCV test (e.g., HCV polymerase chain reaction).\n\nAny of the following tuberculosis (TB)-related conditions:\n\nKnown active TB disease.\n\nHistory of active TB involving any organ system, unless adequately treated per WHO\u002FCDC treatment guidelines and confirmed as fully recovered by consultation with a relevant specialist.\n\nLatent TB infection (LTBI): Participants with LTBI may be rescreened once after receiving at least 4 weeks of appropriate LTBI treatment, provided that no treatment-related hepatotoxicity is evident prior to the first dose of investigational medicinal product (ALT\u002FAST still ≤ 3×ULN).\n\nHistory of lymphoproliferative disorders (e.g., lymphoma) or current symptoms suggestive of lymphoproliferative disorders.\n\nCurrent active malignancy or history of malignancy within 5 years prior to the screening visit, except for squamous cell carcinoma or basal cell carcinoma of the skin, or treated and considered cured in situ cervical cancer.\n\nPresence of other inflammatory diseases, including but not limited to rheumatoid arthritis, hidradenitis suppurativa, inflammatory bowel disease, or systemic lupus erythematosus.\n\nMajor surgery (including joint surgery) within 8 weeks prior to the screening visit, or planned surgery during the study period.\n\nAny systemic disease (e.g., cardiovascular, neurological, renal, hepatic, metabolic, gastrointestinal, hematological, coagulation disorders, immune system disease) that, in the investigator's opinion, is uncontrolled, unstable, or likely to progress to a clinically significant degree during the study.\n\nAny medical or psychiatric condition (including ongoing major depression or active suicidal ideation) that, in the investigator's opinion, may impair the participant's ability to participate in the study.\n\nHistory of chronic alcohol or drug abuse within 6 months prior to the screening visit, as determined by the investigator based on medical history, interview, and examination findings.\n\nCurrent or prior use of IL-17A, IL-17A\u002FF, or IL-23 inhibitors.\n\nReceipt of any live vaccine (including attenuated vaccines) within 8 weeks prior to the baseline visit.\n\nVaccination not permitted during the study and within 17 weeks after the last dose of study treatment.\n\nLaboratory abnormalities at the screening visit, including any of the following:\n\nALT, AST, or ALP ≥ 3×ULN.\n\nBilirubin \\> 1.5×ULN (unconjugated bilirubin \\> 1.5×ULN is acceptable if bilirubin is fractionated and direct bilirubin\u002Ftotal bilirubin ratio is \\\u003C 35%).\n\nWhite blood cell count \\\u003C 3.0×10³\u002FμL.\n\nAbsolute neutrophil count \\\u003C 1.5×10³\u002FμL.\n\nLymphocyte count \\\u003C 500 cells\u002FμL.\n\nHemoglobin \\\u003C 8.5 g\u002FdL.\n\nAny other laboratory abnormality that, in the investigator's opinion, may interfere with the participant's ability to complete the study or confound the interpretation of study results.","ALL","18 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.",[26],"Palmoplantar Pustulosis (PPP)",[28,29,30],"Palmoplantar Pustulosis","Tofacitinib","Imatinib","NOT_YET_RECRUITING","2026-07-30",{"date":34,"type":35},"2026-08-03","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2030-12-30",{"name":41,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100631666","phase-4-clinical-observation-of-xeligekimab-in-the-treatment-of-moderate-to-severe-palmoplantar-pustulosis-100631666","NCT07503652","Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis","Inclusion Criteria:Age: 18 - 75 years old, gender not restricted. Clinically diagnosed PPP for at least 6 months, meeting the diagnostic criteria of Navarini et al. (2017, Br J Dermatol).\n\nModerate to severe PPP: Baseline PPPASI score ≥ 12, PPPIGA score ≥ 3 (moderate or severe).\n\nDermatology Life Quality Index (DLQI) score ≥ 10. Has received at least one local or systemic treatment (such as high-dose corticosteroids, methotrexate) in the past and the treatment was ineffective or intolerable.\n\nThe patient or the patient's family signs the informed consent form. -\n\nExclusion Criteria:oInclude other types of psoriasis (such as pustular, erythrodermic, or punctate).\n\nHave used IL-17A inhibitors within the recent 3 months, or IL-23\u002FTNF-α inhibitors within the past 4 months.\n\nHave severe comorbidities (such as ALT\u002FAST \\> 3 times the upper limit of normal, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\nActive infections (tuberculosis, hepatitis B, hepatitis C, HIV), pregnancy or lactation, drug allergies, participation in other clinical studies, etc.\n\n\\-","75 Years",{"count":52,"type":20},10,[54],"PHASE4","Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of life of patients. Currently, the treatment options for PPP are limited. Traditional therapies such as topical glucocorticoids, phototherapy and oral immunosuppressants have unsatisfactory efficacy, and long-term use may cause significant side effects. The introduction of biologics has provided a new direction for the treatment of PPP, but targeted therapy research for PPP is still scarce, and there are unmet clinical needs. The exploratory study of Xeligekimab in PPP is expected to provide a new treatment option, alleviate symptoms and improve the quality of life of patients. This study takes the domestic Xeligekimab as the research object, aiming to verify its potential in PPP and contribute to the breakthrough of domestic biologics in the field of refractory skin diseases. If the study is successful, it can provide preliminary evidence support for the addition of PPP as an indication for Xeligekimab and offer a preliminary theoretical basis for adding a new option to targeted therapy for PPP.",[26],[58,59],"Xeligekimab","Palmoplantar pustulosis","RECRUITING","2026-03-25",{"date":63,"type":35},"2026-03-31",{"date":65,"type":20},"2026-03",{"date":67,"type":20},"2027-12",{"name":69,"class":42},"First Hospital of China Medical University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100613700","a-prospective-single-arm-open-label-clinical-trial-to-evaluate-the-efficacy-and-safety-of-ivarmacitinib-in-the-treatment-of-palmoplantar-pustulosis-100613700","NCT07270003","A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis","Inclusion Criteria:\n\n* ≥18 years old; clinically\u002Fpathologically confirmed PPP; failure\u002Fintolerance to ≥1 conventional systemic therapy (12-24 weeks of standard dosing); physician-judged suitability for ivarmacitinib; signed informed consent.\n\nExclusion Criteria:\n\n* Lymphocyte count \\\u003C0.5×10⁹\u002FL, neutrophils \\\u003C1×10⁹\u002FL, platelets \\\u003C100×10⁹\u002FL, or hemoglobin \\\u003C80g\u002FL; serum creatinine \\>132.6μmol\u002FL, AST\u002FALT \\>2×ULN, or total bilirubin \\>2.0mg\u002FdL; active infections (tuberculosis, hepatitis B\u002FC, systemic candidiasis); other conditions hindering participation or data interpretation.",{"count":77,"type":20},60,[79],"NA","What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet. It causes red, scaly skin with small, non-infectious blisters (called pustules), and often brings pain, itching, or even joint damage over time. It's more common in women aged 40-58 and makes daily life harder. Right now, treatments for PPP aren't great. Creams (like corticosteroids) make symptoms come back fast. Pills (such as acitretin) work slowly, don't always help, and can have bad side effects. Some strong injectable drugs (biologics) are expensive, need long-term use, and require regular checks for infections-plus they don't work well for many PPP patients.\n\nWhat's this study trying to do?\n\nThis study will test a new pill called ivarmacitinib to see if it works for PPP, and if it's safe. Here's what researchers want to find out:\n\nDoes ivarmacitinib reduce PPP symptoms (like blisters and redness)-and how quickly? Does it help with joint problems that sometimes come with PPP? Are there side effects (like infections, headaches, or stomach issues)? And how common or serious are they? Do things like a patient's age, past treatments, or other health issues affect how well ivarmacitinib works? How will the study work? This is a open study (everyone knows they're taking ivarmacitinib) with 60 patients at the First Affiliated Hospital of Air Force Medical University (China).\n\nWho can join? Must be 18 or older, with a confirmed PPP diagnosis. Tried at least one other standard treatment (like pills or creams) that didn't work or caused too many side effects.\n\nMust not have serious health issues like active infections (e.g., tuberculosis, hepatitis), low blood cell counts, or bad liver\u002Fkidney problems.\n\nWhat will patients do? Take one 4mg ivarmacitinib pill every day for 12 weeks. Can't use other drugs or light therapy for PPP during this time (but simple moisturizers or meds for other health issues are okay).\n\nBefore the study starts: Doctors will check basic health (age, weight, lifestyle), PPP symptoms, and do blood tests, urine tests, and a chest X-ray.\n\nDuring the study (Weeks 1, 2, 4, 8, 12): Doctors will check how symptoms are changing, ask if patients have any side effects, and do another round of blood tests at Week 12.\n\nWhat will researchers look for? Does it work? The main goal is to see how many patients have a 50% or bigger reduction in PPP symptoms by Week 12. They'll also check if symptoms get 75% or 90% better, if joints feel better, and if daily life (like working or sleeping) improves.\n\nIs it safe? Researchers will track all side effects-especially infections, blood clots, stomach aches, or headaches-and how serious they are.",[26],"2025-11-26",{"date":84,"type":35},"2025-12-08",{"date":86,"type":35},"2025-10-01",{"date":88,"type":20},"2026-10-01",{"name":90,"class":42},"Xijing Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100576872","construction-of-a-psoriasis-and-psoriatic-arthritis-diagnostic-model-based-on-multidimensional-nail-information-100576872","NCT06790940","Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information","Inclusion Criteria:\n\n\\-\n\nInclusion criteria for patients with psoriasis:\n\n1. Previous or first-time diagnosis o psoriasis; if previously diagnosed, no restrictions on prior treatments;\n2. Age ≥ 18 and ≤ 80 years, with no gender restrictions;\n3. Consent to participate in this study and sign an informed consent form.\n\nInclusion criteria for non-psoriasis control subjects:\n\n(1) Patients who visit for other non-psoriasis skin conditions such as eczema or acne, and are confirmed by dermatologists not to have psoriasis; (3) Age ≥ 18 and ≤ 80 years, with no gender restrictions; (4) Consent to participate in this study and sign an informed consent form.\n\n\\-\n\nExclusion criteria for patients with psoriasis:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.\n\nExclusion criteria for non-psoriasis subjects:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.",true,"80 Years",{"count":100,"type":20},310,"OBSERVATIONAL","Psoriasis is a globally prevalent chronic relapsing skin disease, characterized by its long duration and tendency to relapse. In addition to skin symptoms, it can also affect nails and joints, leading to pathological features such as pitting, leukonychia, red lunula, or severe nail dystrophy. Some patients with psoriasis may develop psoriatic arthritis. Psoriatic arthritis (PsA) is a chronic relapsing musculoskeletal disease, characterized by psoriatic skin lesions accompanied by axial and peripheral joint damage, and often associated with characteristic manifestations of psoriatic nails. These nail changes typically indicate more severe disease and poorer prognosis. However, current diagnostic methods largely depend on the experience and professional knowledge of clinicians, which are subjective and uncertain. Moreover, histopathological examination is invasive and can cause additional pain and inconvenience to patients.\n\nTo develop an effective, convenient, and non-invasive early diagnostic tool for psoriasis, our research team has conducted in-depth studies in the field of psoriasis-related diagnosis and predictive models. We have successfully developed a predictive model for psoriatic arthritis, including six key predictive factors: history of joint swelling, history of arthritis, history of swelling and pain in fingers or toes, nail involvement, genital involvement, and a history of long-term local use of corticosteroids. Clinicians can effectively assess the risk of psoriatic arthritis by obtaining information about these six factors from patients. The paper \"Early detection of psoriatic arthritis in patients with psoriasis: construction of a multifactorial prediction model\" was published in Front. Immunol (DOI: 10.3389\u002Ffimmu.2024.1426127).\n\nRaman spectroscopy is a rapid, non-invasive molecular vibration detection method that has shown great potential in medical diagnostics. Studies have shown that Raman spectroscopy can distinguish normal and abnormal tissues at the molecular level and has been proven feasible in nail testing. For psoriasis, a disease that causes significant nail changes, Raman spectroscopy offers unique advantages.\n\nBased on this background, our project will conduct a prospective observational study on psoriasis and psoriatic arthritis using multidimensional nail data. We will integrate Raman spectroscopy data of nails and multidimensional clinical information and apply artificial intelligence algorithms to develop a new diagnostic tool for psoriasis and psoriatic arthritis. This tool aims to improve the accuracy and efficiency of diagnosis, providing strong support for the early detection and precise treatment of psoriasis and psoriatic arthritis.",[104,105,26,106],"Psoriasis (PsO)","Psoriatic Arthritis","Plaque Psoriasis","2025-01-23",{"date":109,"type":35},"2025-01-24",{"date":111,"type":20},"2025-01-20",{"date":113,"type":20},"2026-12-01",{"name":115,"class":42},"Shanghai Yueyang Integrated Medicine Hospital"]